PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
Rosa A. van Amerongen(Leiden University Medical Center), Mirjam H.M. Heemskerk(Leiden University Medical Center)
Cited by 21
Related Papers
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19
|Nature Immunology|2021|130
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
|Journal for ImmunoTherapy of Cancer|2022|23
Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential
|Molecular Therapy — Methods & Clinical Development|2023|15